Principal Investigators

Melanie Börries

Principal Investigator

Institute of Medical Bioinformatics and Systems Medicine
Medical Center University of Freiburg

Breisacher Str. 153
79110 Freiburg

Current position

Director (Institutsdirektorin) W3 Professor for Medical Bioinformatics at the University of Freiburg, Institute of Medical Bioinformatics and Systems Medicine, Medical Center University of Freiburg

Academic training

2001 - 2005Studies of Cell Biology, MD/PhD Program at the University of Basel, Switzerland
1994 - 2001Studies of Human Medicine, University of Lübeck

Advanced academic qualifications

2005Doctoral degree in Cell Biology (Dr. phil), Biozentrum, University of Basel, Switzerland
2004Doctoral degree in Medicine (Dr. med.), University of Lübeck

Postgraduate Positions

Since 2025 Deputy Spokesperson for the DKTK
Since 2024Spokesperson of the DKTK (German Cancer Consortium) Partner Site Freiburg
Since 2021Co-Director of the Tumor Center Freiburg – CCCF
Since 2019Director of the Institute of Medical Bioinformatics and Systems Medicine
Since 2019W3-Professor for Medical Bioinformatics, Medical Faculty, University of Freiburg
2013 - 2019Group leader at the DKTK/DKFZ Partner Site Freiburg, Institute of Molecular Medicine and Cell Research, University of Freiburg
2009-2012FRIAS, Principal Investigator together with Hauke Busch (CCC Group), Institute for Advanced Studies-LIFENET, University of Freiburg, Germany
2005-2009Institute for Pharmacology and Toxicology, University of Freiburg (2007-2009: parental leave), Germany
2001-2005Physician in Training/Clinical Resident, Department of Cardiology, Inselspital, University of Bern, Switzerland (3 month/year, MD PhD program)

Miscellaneous (Honors, Awards)

2025Deutscher Krebspreis (German Cancer Award 2025, DKG)
2018Granted Patent “Method for characterization of modifications caused by the use of designer nucleases, # EP 18196438.8, filed on September 25, 2018
2006Award for innovative teaching projects
2001 - 2005Doctoral scholarship (MD/PhD) of the Maurice E Müller Stiftung, Switzerland

Publications listed in PubMed®

Show publications by Melanie Börries

Publications (based on CRC1479 funding)

Poggio T, Gräßel L, Andrieux G, Gómez Martínez AM, Stock K, Kršić M, Gonzalez Menendez I, Kreutmair S, Orcinha C, Russ M, Yacob S, Miething C, Bonofiglio F, Montes-Mojarro IA, Köhler N, Follo M, Pfeifer D, Fend F, Quintanilla-Martinez L, Chiarle R, Voena C, Jung J, Zeiser R, Turner SD, Boerries M, Duyster J, Illert AL. CD4+ T cells orchestrate the immune response to ALK-positive T-cell lymphoma. Blood. 2026 Jul 28:blood.2026033240. doi: 10.1182/blood.2026033240. Epub ahead of print
Gawron J, Czech M, Rückert T, Holzmüller V, Andreev G, Burk AC, Hartmann A, Chatterjee S, Andrieux G, Marquard FE, Baur AS, Stell AV, Krausz M, Braun LM, Osswald N, Melchinger W, Wertheimer T, Proano-Vasco AI, Maas-Bauer K, Schmitt-Graeff A, Boerries M, Köhler N, Ayuk FA, Schell C, Quante M, Zeiser R. Gastrin for the treatment of acute graft-versus-host disease of the stomach. Blood. 2026 Apr 9;147(15):1763-1778. doi: 10.1182/blood.2025031080.

 

Highlighted by: Chakraverty R. GVHD fails the acid test. Blood. 2026 Apr 9;147(15):1660-1662.
Heitmann JS, Maringer Y, Jung S, Wacker M, Hackenbruch C, Polster M, Marconato M, Nelde A, Bauer J, Zwick M, Baur AS, Metzger A, Krolla C, Andrieux G, Köhler N, Boerries M, Denk M, Zieschang L, Kammer C, Hoenisch-Gravel N, Richter M, Oezbek MT, Wirths S, Dengler A, Dubbelaar ML, Pumptow M, Martus P, Brüggemann M, Rammensee HG, Salih HR, Walz JS. Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study. Lancet Haematol. 2026 Feb;13(2):e74-e85. doi: 10.1016/S2352-3026(25)00323-0. Epub 2026 Jan 14. Erratum in: Lancet Haematol. 2026 Feb;13(2):e58. doi: 10.1016/S2352-3026(26)00012-8.
Li X, Lebeaupin C, Kadianaki A, Druelle-Cedano C, Vesper N, Rennert C, Huguet-Pradell J, Gomez Ramos B, Fan C, Piecyk RS, Zizmare L, Ramadori P, Li L, Frick L, Qiu M, Zhang C, Martins Nascentes Melo L, Ranvir VP, Shen P, Hanselmann J, Kosla J, Fernández-Vaquero M, Vucur M, Baskaran P, Bao X, Coleman OI, Tang Y, Cetin M, Chen Z, Jang I, Del Prete S, Rahbari M, Zhang P, Pham TV, Hou Y, Sun A, Gu L, Kim LC, Rothermel U, Heide D, Ali A, Gallage S, Talvard-Balland N, Piqué-Gili M, Gris-Oliver A, Bevilacqua A, Schlicker L, Duffey A, Unger K, Szydlowska M, Hetzer J, Odom DT, Machauer T, Bucci D, Sant P, Lee JH, Rösler J, Meckelmann SW, Schreck J, Murray S, Simon MC, Nahnsen S, Schulze A, Ho PC, Jugold M, Breuhahn K, Mallm JP, Schirmacher P, Roth S, Rahbari N, Tschaharganeh DF, Roessler S, Goeppert B, Bengsch B, Andrieux G, Boerries M, Malek NP, Prinz M, Weber A, Zeiser R, Tamayo P, Bronsert P, Kurowski K, Thimme R, Yuan D, Carretero R, Luedde T, Pinyol R, Hartmann FJ, Karin M, Tasdogan A, Trautwein C, Mall M, Hofmann M, Llovet JM, Haller D, Kaufman RJ, Heikenwälder M. Activated ATF6α is a hepatic tumour driver restricting immunosurveillance. Nature. 2026 Mar;651(8106):796-807. doi: 10.1038/s41586-025-10036-8. Epub 2026 Feb 4.
Fetsch V, Schwöbel L, Ozyerli-Goknar E, Stell AV, Punta M, Plenge T, Klaus T, Gupta MK, Andrieux G, Shoumariyeh K, Pfeiffer S, Corrales E, Schlenke L, Baniadam H, Brandl SM, Andreis M, Remen M, Hartmann A, Grueter K, Zwick M, Köhler N, Kuban M, Metzger E, Rummelt C, Duyster J, Boerries M, Hofmann M, Färber J, Braun LM, Zähringer A, Lübbert M, Toffalori C, Vago L, Heidel FH, Minguet S, Apostolova P, Feuchtinger T, Maas-Bauer K, Blaeschke F, Kühn MWM, Timmers HTM, Wertheimer T, Perner F, Zeiser R. Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML. Blood. 2026 Jan 29;147(5):584-601. doi: 10.1182/blood.2025029712.

 

Highlighted by: Chakraverty R. Menin inhibitors: a 2-in-1 defense versus AML immune evasion. Blood (2026) 147 (5): 482–483.
Traichel J, Metzger A, Walz M, Feuerstein R, Wohlfeil N, Metzger P, Marx L, Asdih C, Lindenthal A, Seger A, Schrimpf J, Nardella LL, Kowar S, Frew IJ, Halbach S, Kesselring R, Boerries M, Griffin R, Brummer T. Novel syngeneic cell lines for studying high-risk BRAFV600E-driven colorectal cancer in vivo. Cancer Res Commun. 2026 Jan 22. doi: 10.1158/2767-9764.CRC-25-0599. Epub ahead of print.
Hafner P, Keller SJ, Chen X, Alrawashdeh A, Jumaa H, Nollmann FI, Besson S, Kemming J, Gorka O, Das T, Appiah B, Lehmann A, Li M, Apostolova P, Bengsch B, Zeiser R, Tholen S, Schilling O, Groß O, Vlachos A, Wittel UA, von Elverfeldt D, Reichardt W, Boerries M, Andrieux G, Heynen GJ, Fichtner-Feigl S, Hannibal L, Ruess DA. Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. Signal Transduct Target Ther. 2026 Jan 16;11(1):33. doi: 10.1038/s41392-025-02563-7.
Zwick M, Zinkel B, Spohr C, Rückert T, Halbach S, Shoumariyeh K, Scheid J, Baur AS, Braun LM, Angel M, Michaeli E, Todkar A, Nelde A, Märklin M, Holzmayer SJ, Dicks S, Boerries M, Duquesne S, Schlaak AE, Otto-Mora P, Bengsch B, Schiff M, Kissel S, Selle M, Follo M, Altmann H, Kunadt D, Illert AL, Walz JS, Walz G, Duyster J, Schetelig J, Brummer T, Zeiser R, Köhler N. FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia. Cancer Res. 2026 Jan 16;86(2):367-386. doi: 10.1158/0008-5472.CAN-25-0349.
Tangermann C, Ghosh A, Ziegler M, Facchinetti F, Stappenbeck J, Carus Sahin YO, Riester M, Viardot LC, Zundel T, Friboulet L, Hollebecque A, Naveja JJ, Wanninger A, Hess ME, Brummer T, Boerries M, Loges S, Loriot Y, Illert AL, Diederichs S. Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations. Nat Genet. 2026 Jan;58(1):157-168. doi: 10.1038/s41588-025-02431-8. Epub 2025 Dec 8.

Chatterjee S, Rückert T, Martin I, Michaeli E, Buescher J, Apostolova P, Erny D, Lalioti ME, Biavasco F, Hartmann A, Runge S, Braun LM, Talvard-Balland N, Adams RC, Schmitt-Graeff A, Cook J, Wenger V, Athanassopoulos D, Hasavci D, Vallejo-Janeta AP, Blank T, Schaible P, Vinnakota JM, Zähringer A, Ganal-Vonarburg SC, Melchinger W, Pfeifer D, Köhler N, Rosshart SP, Michonneau D, Socié G, Andrieux G, Cabezas-Wallscheid N, Boerries M, Prinz M, Zeiser R. Gut microbiota-derived TMAVA is a modulator of acute CNS-GVHD. J Exp Med. 2025 Sep 1;222(9):e20242180. doi: 10.1084/jem.20242180. Epub 2025 Jul 8.
Peighambari A, Huang H, Metzger P, Adlesic M, Zodel K, Schäfer S, Seidel P, Braun LM, Hülsdünker J, Melchinger W, Follo M, Ku M, Haug S, Li Y, Köttgen A, Schell C, von Elverfeldt D, Reichardt W, Zeiser R, Heikenwalder M, Höfflin R, Börries M, Frew IJ. Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance. Sci Rep. 2025 Jun 5;15(1):19818. doi: 10.1038/s41598-025-04917-1.

Zähringer A, Morgado I, Erny D, Ingelfinger F, Gawron J, Chatterjee S, Wenger V, Schmidt D, Schwöbel LF, Adams RC, Langenbach M, Hartmann A, Osswald N, Wolf J, Schlunck G, Briquez PS, Grueter K, Ruess DA, Frew I, Burk AC, Holzmüller V, Grimbacher B, Michonneau D, Andrieux G, Socié G, Kolter J, Börries M, Follo M, Blaeschke F, Sevenich L, Prinz M, Zeiser R, Vinnakota JM. AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling. Blood Adv. 2025 Mar 31:bloodadvances.2024015000. doi: 10.1182/bloodadvances.2024015000. Epub ahead of print.

Müller M, Zodel K, Abhari BA, Cuomo F, Nizamuddin S, Metzger P, Boerries M, Timmers HTM, Frew IJ. KDM5C and KDM5D mutations have different consequences in clear cell renal cell carcinoma cells. Commun Biol. 2025 Feb 15;8(1):244. doi: 10.1038/s42003-025-07695-8.

Braun LM, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, Rückert T, Unger S, Kreutmair S, Zwick M, Follo M, Hartmann A, Osswald N, Melchinger W, Chapman S, Hutchinson JA, Haferkamp S, Torster L, Kött J, Gebhardt C, Hellwig D, Karantzelis N, Wallrabenstein T, Lowinus T, Yücel M, Brehm N, Rawluk J, Pfeifer D, Bronsert P, Rogg M, Mattern S, Heikenwälder M, Fusco S, Malek NP, Singer S, Schmitt-Graeff A, Ceteci F, Greten FR, Blazar BR, Boerries M, Köhler N, Duyster J, Ihorst G, Lassmann S, Keye P, Minguet S, Schadendorf D, Ugurel S, Rafei-Shamsabadi D, Thimme R, Hasselblatt P, Bengsch B, Schell C, Pearce EL, Meiss F, Becher B, Funke-Lorenz C, Placke JM, Apostolova P, Zeiser R. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell. 2025 Feb 10;43(2):269-291.e19. doi: 10.1016/j.ccell.2025.01.004.
Catalano A, Haas LS, Zodel K, Adlesic M, Cuomo F, Peighambari A, Metzger P, Huang H, Haug S, Köttgen A, Köhler N, Boerries M, Frew IJ. Mutations in tumor suppressor genes Vhl and Rassf1a cause DNA damage, chromosomal instability and induce gene expression changes characteristic of clear cell renal cell carcinoma. Kidney Int. 2024 Dec 24:S0085-2538(24)00912-8. doi: 10.1016/j.kint.2024.12.003. Epub ahead of print.
Zhang Z, Langenbach M, Sagar S, Fetsch V, Stritzker J, Severa E, Meng K, Winkler F, Rana N, Zoldan K, Godbole I, Solis S, Weber JS, Rafei-Shamsabadi D, Lehr S, Diehl R, Venhoff AC, Voll RE, Buettner N, Neumann-Haefelin C, Boettler T, Hofmann M, Boerries M, Meiss F, Zeiser R, Thimme R, Herati RS, Bengsch B. Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells. Nat Immunol. 2024 Dec 19. doi: 10.1038/s41590-024-02027-0. Epub ahead of print.
Talvard-Balland N, Braun LM, Dixon KO, Zwick M, Engel H, Hartmann A, Duquesne S, Penter L, Andrieux G, Rindlisbacher LS, Acerbis A, Ehmann J, Köllerer C, Ansuinelli M, Rettig A, Moschallski K, Apostolova P, Brummer T, Illert AL, Schramm MA, Cheng Y, Köttgen A, Duyster J, Menssen HD, Ritz J, Blazar BR, Boerries M, Schmitt Graeff A, Sariipek N, van Galen P, Buescher JM, Cabezas-Wallscheid N, Pahl HL, Pearce EL, Soiffer RJ, Wu CJ, Vago L, Becher B, Köhler N, Wertheimer T, Kuchroo VK, Zeiser R. Oncogene induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice. J Clin Invest. 2024 Jun 25:e177460. doi: 10.1172/JCI177460. Epub ahead of print.
Schmidt D, Endres C, Hoefflin R, Andrieux G, Zwick M, Karantzelis N, Staehle HF, Vinnakota JM, Duquesne S, Mozaffari Jovein M, Pfeifer D, Becker H, Blazar BR, Zähringer A, Duyster J, Brummer T, Boerries M, Baumeister J, Shoumariyeh K, Li J, Green AR, Heidel FH, Tirosh I, Pahl HL, Leimkühler N, Köhler N, de Toledo MAS, Koschmieder S, Zeiser R. Oncogenic Calreticulin Induces Immune Escape by Stimulating TGF-β Expression and Regulatory T Cell Expansion in the Bone Marrow Microenvironment. Cancer Res. 2024 Jun 17. doi: 10.1158/0008-5472.CAN-23-3553. Epub ahead of print.
Vinnakota JM, Adams RC, Athanassopoulos D, Schmidt D, Biavasco F, Zähringer A, Erny D, Schwabenland M, Langenbach M, Wenger V, Salié H, Cook J, Mossad O, Andrieux G, Dersch R, Rauer S, Duquesne S, Monaco G, Wolf P, Blank T, Häne P, Greter M, Becher B, Henneke P, Pfeifer D, Blazar BR, Duyster J, Boerries M, Köhler N, Chhatbar CM, Bengsch B, Prinz M, Zeiser R. Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation. Sci Transl Med. 2024 Jun 12;16(751):eadj9672. doi: 10.1126/scitranslmed.adj9672. Epub 2024 Jun 12. PMID: 38865481.
Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Schmidt D, Fetsch V, Zähringer A, Salié H, Athanassopoulos D, Braun LM, Javorniczky NR, Ho JNHG, Kierdorf K, Marks R, Wäsch R, Simonetta F, Andrieux G, Pfeifer D, Monaco G, Capitini C, Fry TJ, Blank T, Blazar BR, Wagner E, Theobald M, Sommer C, Stelljes M, Reicherts C, Jeibmann A, Schittenhelm J, Monoranu CM, Rosenwald A, Kortüm M, Rasche L, Einsele H, Meyer PT, Brumberg J, Völkl S, Mackensen A, Coras R, von Bergwelt-Baildon M, Albert NL, Bartos LM, Brendel M, Holzgreve A, Mack M, Boerries M, Mackall CL, Duyster J, Henneke P, Priller J, Köhler N, Strübing F, Bengsch B, Ruella M, Subklewe M, von Baumgarten L, Gill S, Prinz M, Zeiser R. Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat Cancer. 2024 May 13. doi: 10.1038/s43018-024-00764-7. Epub ahead of print.
Czech M, Schneider S, Peltokangas N, El Khawanky N, Ghimire S, Andrieux G, Hülsdünker J, Krausz M, Proietti M, Braun LM, Rückert T, Langenbach M, Schmidt D, Martin I, Wenger V, de Vega E, Haring E, Pourjam M, Pfeifer D, Schmitt-Graeff A, Grimbacher B, Aumann K, Kircher B, Tilg H, Raffatellu M, Thiele Orberg E, Häcker G, Duyster J, Köhler N, Holler E, Nachbaur D, Boerries M, Gerner RR, Grün D, Zeiser R. Lipocalin-2 expression identifies an intestinal regulatory neutrophil population during acute graft-versus-host disease. Sci Transl Med. 2024 Feb 21;16(735):eadi1501. doi: 10.1126/scitranslmed.adi1501. Epub 2024 Feb 21.
Maas-Bauer K, Stell AV, Yan KL, de Vega E, Vinnakota JM, Unger S, Núñez N, Norona J, Talvard-Balland N, Koßmann S, Schwan C, Miething C, Martens US, Shoumariyeh K, Nestor RP, Duquesne S, Hanke K, Rackiewicz M, Hu Z, El Khawanky N, Taromi S, Andrlova H, Faraidun H, Walter S, Pfeifer D, Follo M, Waldschmidt J, Melchinger W, Rassner M, Wehr C, Schmitt-Graeff A, Halbach S, Liao J, Häcker G, Brummer T, Dengjel J, Andrieux G, Grosse R, Tugues S, Blazar BR, Becher B, Boerries M, Zeiser R. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease. Nat Commun. 2024 Jan 10;15(1):446. doi: 10.1038/s41467-024-44703-7.

Velasco Cárdenas RM, Brandl SM, Meléndez AV, Schlaak AE, Buschky A, Peters T, Beier F, Serrels B, Taromi S, Raute K, Hauri S, Gstaiger M, Lassmann S, Huppa JB, Boerries M, Andrieux G, Bengsch B, Schamel WW, Minguet S. Harnessing CD3 diversity to optimize CAR T cells. Nat Immunol. 2023 Nov 6. doi: 10.1038/s41590-023-01658-z. Epub ahead of print.

Nelde A, Schuster H, Heitmann JS, Bauer J, Maringer Y, Zwick M, Volkmer JP, Chen JY, Stanger AMP, Lehmann A, Appiah B, Märklin M, Rücker-Braun E, Salih HR, Roerden M, Schroeder SM, Häring MF, Schlosser A, Schetelig J, Schmitz M, Boerries M, Köhler N, Lengerke C, Majeti R, Weissman IL, Rammensee HG, Walz JS. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Blood Cancer Discov. 2023 Nov 1;4(6):468-489. doi: 10.1158/2643-3230.BCD-23-0020.
Lauinger M, Christen D, Klar RFU, Roubaty C, Heilig CE, Stumpe M, Knox JJ, Radulovich N, Tamblyn L, Xie IY, Horak P, Forschner A, Bitzer M, Wittel UA, Boerries M, Ball CR, Heining C, Glimm H, Fröhlich M, Hübschmann D, Gallinger S, Fritsch R, Fröhling S, O’Kane GM, Dengjel J, Brummer T. BRAFΔβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability. Sci Adv. 2023 Sep;9(35):eade7486. doi: 10.1126/sciadv.ade7486. Epub 2023 Sep 1.
Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk AC, Wehr C, Maas-Bauer K, Melchinger W, Haring E, Hoefflin R, Shoumariyeh K, Hupfer V, Lauer EM, Duquesne S, Lowinus T, Gonzalo Núñez N, Alberti C, da Costa Pereira S, Merten CH, Power L, Weiss M, Böke C, Pfeifer D, Marks R, Bertz H, Wäsch R, Ihorst G, Gentner B, Duyster J, Boerries M, Andrieux G, Finke J, Becher B, Vago L, Zeiser R. Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response. Br J Haematol. 2023 Aug 4. doi: 10.1111/bjh.19007. Epub ahead of print.

Raute K, Strietz J, Parigiani MA, Andrieux G, Thomas OS, Kistner KM, Zintchenko M, Aichele P, Hofmann M, Zhou H, Weber W, Boerries M, Swamy M, Maurer J, Minguet S. Breast Cancer Stem Cell-Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands. Cancer Immunol Res. 2023 May 4:OF1-OF20. doi: 10.1158/2326-6066. CIR-22-0296. Epub ahead of print.

Langenbach M, Giesler S, Richtsfeld S, da Costa-Pereira S, Rindlisbacher L, Wertheimer T, Braun LM, Andrieux G, Duquesne S, Pfeifer D, Woessner NM, Menssen HD, Taromi S, Duyster J, Boerries M, Brummer T, Blazar BR, Minguet S, Turko P, Levesque MP, Becher B, Zeiser R. MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL-15 and MHC class II production. Mol Cancer Res. 2023 Apr 18:MCR-22-0898. doi: 10.1158/1541-7786.MCR-22-0898. Epub ahead of print.

Jaeger A, Gambheer SMM, Sun X, Chernyakov D, Skorobohatko O, Mack TM, Kissel S, Pfeifer D, Zeiser R, Fisch P, Andrieux G, Bräuer-Hartmann D, Bauer M, Schulze S, Follo M, Boerries M, von Bubnoff N, Miething C, Hidalgo JV, Klein C, Weber T, Wickenhauser C, Binder M, Dierks C. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood. 2023 Jan 25:blood.2022015653. doi: 10.1182/blood.2022015653.

Seidel P, Rubarth A, Zodel K, Peighambari A, Neumann F, Federkiel Y, Huang H, Hoefflin R, Adlesic M, Witt C, Hoffmann DJ, Metzger P, Lindemann RK, Zenke FT, Schell C, Boerries M, von Elverfeldt D, Reichardt W, Follo M, Albers J, Frew IJ. ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma. JCI Insight. 2022 Dec 22;7(24):e156087. doi: 10.1172/jci.insight.156087.

Rückert T, Andrieux G, Boerries M, Hanke-Müller K, Woessner NM, Doetsch S, Schell C, Aumann K, Kolter J, Schmitt-Graeff A, Schiff M, Braun LM, Haring E, Kissel S, Siranosian BA, Bhatt AS, Nordkild P, Wehkamp J, Jensen BAH, Minguet S, Duyster J, Zeiser R, Köhler N. Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci Transl Med. 2022 Dec 21;14(676):eabp9675. doi: 10.1126/scitranslmed.abp9675. Epub 2022 Dec 21. PMID: 36542690.

free full text: https://www.science.org/stoken/author-tokens/ST-951/full

Bauer J, Köhler N, Maringer Y, Bucher P, Bilich T, Zwick M, Dicks S, Nelde A, Dubbelaar M, Scheid J, Wacker M, Heitmann JS, Schroeder S, Rieth J, Denk M, Richter M, Klein R, Bonzheim I, Luibrand J, Holzer U, Ebinger M, Brecht IB, Bitzer M, Boerries M, Feucht J, Salih HR, Rammensee HG, Hailfinger S, Walz JS. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat Commun. 2022 Oct 27;13(1):6401. doi: 10.1038/s41467-022-33746-3.

Ho JNHG, Schmidt D, Lowinus T, Ryoo J, Dopfer EP, Gonzalo Núñez N, Costa-Pereira S, Toffalori C, Punta M, Fetsch V, Wertheimer T, Rittmann MC, Braun LM, Follo M, Briere C, Vinnakota JM, Langenbach M, Koppers F, Shoumariyeh K, Engel H, Rückert T, Märklin M, Holzmayer S, Illert AL, Magon F, Andrieux G, Duquesne S, Pfeifer D, Staniek J, Rizzi M, Miething C, Köhler N, Duyster J, Menssen HD, Boerries M, Buescher JM, Cabezas-Wallscheid N, Blazar BR, Apostolova P, Vago L, Pearce EL, Becher B, Zeiser R. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. Blood. 2022 Sep 8;140(10):1167-1181. doi: 10.1182/blood.2022016082.

Highlighted by this Editorial: Bleakley M, Biernacki M. MDM2 inhibition augments GVL effect. Blood. 2022 Sep 8;140(10):1064-1065. doi: 10.1182/blood.2022017724. PMID: 36074535.

Aktories P, Petry P, Glatz P, Andrieux G, Oschwald A, Botterer H, Gorka O, Erny D, Boerries M, Henneke P, Groß O, Prinz M, Kierdorf K. An improved organotypic cell culture system to study tissue-resident macrophages ex vivo. Cell Rep Methods. 2022 Jul 26;2(8):100260. doi: 10.1016/j.crmeth.2022.100260.

Haring E, Andrieux G, Uhl FM, Krausz M, Proietti M, Sauer B, Esser PR, Martin SF, Pfeifer D, Schmitt-Graeff A, Duyster J, Köhler N, Grimbacher B, Boerries M, Aumann K, Zeiser R, Apostolova P. Therapeutic targeting of endoplasmic reticulum stress in acute graft-versus-host disease. Haematologica. 2022 Jul 1;107(7):1538-1554. doi: 10.3324/haematol.2021.278387.

Flum M, Dicks S, Teng YH, Schrempp M, Nyström A, Boerries M, Hecht A. Canonical TGFβ signaling induces collective invasion in colorectal carcinogenesis through a Snail1- and Zeb1-independent partial EMT. Oncogene. 2022 Mar;41(10):1492-1506. doi: 10.1038/s41388-022-02190-4.

Corrales E, Levit-Zerdoun E, Metzger P, Kowar S, Ku M, Brummer T, Boerries M. Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts. Cell Commun Signal. 2021 Dec 20;19(1):123. doi: 10.1186/s12964-021-00801-3.

Spohr C, Poggio T, Andrieux G, Schönberger K, Cabezas-Wallscheid N, Boerries M, Halbach S, Illert AL, Brummer T. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo. Leukemia. 2022 Apr;36(4):970-982. doi: 10.1038/s41375-021-01490-0. Epub 2021 Dec 13.2021

Grünwald BT, Devisme A, Andrieux G, Vyas F, Aliar K, McCloskey CW, Macklin A, Jang GH, Denroche R, Romero JM, Bavi P, Bronsert P, Notta F, O’Kane G, Wilson J, Knox J, Tamblyn L, Udaskin M, Radulovich N, Fischer SE, Boerries M, Gallinger S, Kislinger T, Khokha R. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 2021 Oct 28;184(22):5577-5592.e18. doi: 10.1016/j.cell.2021.09.022. Epub 2021 Oct 12.2021.

Contact

Dr. Annika Warncke

+49 (0) 761 270-71940 annika.warncke@uniklinik-freiburg.de
Logo DFG Deutsche Forschungsgemeinschaft
Logo Albert-Ludwigs-Universität Freiburg
Logo Universitätsklinikum Freiburg
Logo Universitätsklinikum Tübingen
Logo Georg Speyer Haus Frankfurt
Logo Deutsches Krebsforschungszentrum Heidelberg
Logo Universitätsklinikum Heidelberg
© 2026 SFB 1479 - OncoEscape